Influence of genetic polymorphisms in patients with chronic kidney disease on the pharmacokinetics and pharmacodynamics of atorvastatin

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000041391

Enrollment

Unknown

Registered

2020-12-24

Start date

2014-05-01

Completion date

Unknown

Last updated

2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

case series:atorvastatin 20mg qn

case series:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 78 Years

Inclusion criteria

Inclusion criteria: 1.Aged >= 50 years, eGFR = 50, eGFR >= 60 mL·min-1·1.73m-2 chronic kidney disease patients; 3.CKD patients aged 18to49 years,without dialysis or kidney transplants,have with one of the following: a.have known coronary artery disease (myocardial infarction or coronary remodeling); b.diabetes; c.ischemic stroke; d.the incidence of coronary death or fatal myocardial infarction is estimated to be greater than 10 in 10 years; 4.Dialysis for patients with CKD,LDL-C > 3.37mmol/L. In accordance with 1,2,3 and any of 4, can be included in the study.

Exclusion criteria

Exclusion criteria: 1.Pregnant and breastfeeding women; 2.Patients with active liver disease; 3.People who are allergic to statins; 4.The patients are already taking statins; 5.Taking other lipid-regulating drugs: niacin, Bate and its derivatives, Probucol, fish oil, bile acid-binding resin; 6.Drugs that may increase the risk of myopathy: cyclosporine ,human immunodeficiency virus (HIV) protease inhibitors (tipranavir and ritonavir,lopinavir and ritonavir,saquinavir and ritonavir*,darunavir and ritonavir,foxanavir,foxanavir and ritonavir,nelfinavir),hepatitis C protease inhibitor(telaprevir),clarithromycin,itraconazole,hepatitis C protease inhibitor(Boceprevir); 7.Other medications that may affect blood biochemical measurements:human immunodeficiency virus (HIV) protease inhibitors (lopinavir, darunavir,ritonavir) ,azole antifungal drugs (itraconazole,ketoconazole), macrolide anti-infective drugs (erythromycin, clarithromycin, telithromycin),fibrates (gemfibrozil,bezafibrate), niacin, nefazodone, cyclosporin, amiodarone, diltiazem, fusidic acid,etc; 8.Cholestatic diseases; 9.Blood system diseases; 10.Neoplasm; 11.Hypothyroidism; 12.Gastrointestinal diseases.

Design outcomes

Primary

Measure	Time frame
Atorvastatin blood concentration;Triglycerides;High density lipoprotein cholesterol;Low density lipoprotein cholesterol;Total cholesterol;	—

Countries

China

Contacts

Public ContactZheng Fuchun

The First Affiliated Hospital of Shantou University Medical College

zhengfc@stu.edu.cn+86 13902734162

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026